Replies to post #15711 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Could be a simple bounceback from yesterday's (kneejerk) sell-off.

Might also be b/c I tweeted the contents of #msg-124324773 :- )

[GrthzGd]

Nothing obviously great in yesterday's earnings call. Their expected $60 MM milestone payment from Mylan for M834, the Orencia biosimilar, in the second half of 2016 is a good thing though.